智飞生物,300122,收入构成,报告日期,2020-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,1515614,925832,589782,38.91%,99.59% 服务费收入,3423,969,2453,71.68%,0.41% 智飞生物,300122,收入构成,报告日期,2019-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,1052541,611817,440724,41.87%,99.01% 服务费收入,6191,1764,4427,71.5%,0.99% 智飞生物,300122,收入构成,报告日期,2019-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 代理产品非免疫规划苗,442307,292011,150296,33.98%,72.69% 自主产品非免疫规划苗,57478,3739,53739,93.49%,25.99% 其他(补充),3298,573,2725,82.64%,1.32% 智飞生物,300122,收入构成,报告日期,2018-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,515794,234383,281411,54.56%,98.28% 其他(补充),7037,2110,4927,70.01%,1.72% 智飞生物,300122,收入构成,报告日期,2017-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,129238,22199,107038,82.82%,101.51% 冷链运输行业,-- ,503,-503,--,-0.48% 其他(补充),5019,6103,-1084,-21.6%,-1.03% 智飞生物,300122,收入构成,报告日期,2017-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 自主产品二类苗,41528,2030,39498,95.11%,98.03% 其他(补充),1860,1067,793,42.64%,1.97% 智飞生物,300122,收入构成,报告日期,2016-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务费,424,262,163,38.34%,0.4% 生物制品,44170,3260,40910,92.62%,99.6% 智飞生物,300122,收入构成,报告日期,2016-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),63,16,47,74.08%,0.28% 生物制品,18331,1619,16712,91.17%,99.72% 智飞生物,300122,收入构成,报告日期,2015-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务费,1202,247,955,79.47%,1.67% 生物制品,70072,13930,56142,80.12%,98.33% 智飞生物,300122,收入构成,报告日期,2015-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,37752,11078,26674,70.66%,97.93% 其他(补充),710,145,565,79.52%,2.07% 智飞生物,300122,收入构成,报告日期,2014-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),5540,1072,4468,80.65%,9.12% 生物制品,74554,30007,44546,59.75%,90.88% 智飞生物,300122,收入构成,报告日期,2014-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),2771,-- ,2771,--,11.56% 生物制品,35279,14089,21190,60.06%,88.44% 智飞生物,300122,收入构成,报告日期,2013-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),7032,1364,5668,80.6%,12.01% 生物制品,70986,29441,41544,58.53%,87.99% 智飞生物,300122,收入构成,报告日期,2013-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),3266,-- ,3266,--,13.42% 生物制品,39292,18225,21067,53.62%,86.58% 智飞生物,300122,收入构成,报告日期,2012-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),3043,609,2434,79.99%,5.71% 内部抵销数,-11572,-11744,172,-1.48%,0.4% 生物制品,84992,44960,40031,47.1%,93.89% 智飞生物,300122,收入构成,报告日期,2012-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,41589,24614,16975,40.82%,97.79% 内部抵销数,-9300,-9175,-125,1.35%,-0.72% 其他(补充),510,-- ,510,--,2.94% 智飞生物,300122,收入构成,报告日期,2011-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),3762,757,3005,79.88%,7.95% 减:内部抵销数,-16006,-15849,-157,0.98%,-0.41% 生物制品,75118,40151,34968,46.55%,92.47% 智飞生物,300122,收入构成,报告日期,2010-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 减:内部抵销数,-8612,-8613,1,-0.01%,0.01% 其他产品,1,1,0,22%,0% A群C脑膜炎球菌多糖疫苗,79,36,43,54.36%,0.2% 甲型肝炎减毒活疫苗,1554,641,914,58.78%,4.27% B型流感嗜血杆菌,25299,17096,8203,32.42%,38.3% 注射用母牛分枝杆菌(微卡),1868,252,1616,86.51%,7.54% ACYW135群脑膜炎球菌多糖疫苗,8229,269,7961,96.74%,37.17% A群C群脑膜炎球菌多糖结合疫苗,2893,214,2679,92.59%,12.51% 智飞生物,300122,收入构成,报告日期,2009-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 减:内部抵销数,-13655,-13730,75,-0.55%,0.19% 其他产品,36,11,25,70.74%,0.06% 麻腮风三联,1476,611,864,58.57%,2.18% 麻风二联,2,1,2,71%,0% A群C脑膜炎球菌多糖疫苗,70,25,45,63.91%,0.11% 甲型肝炎减毒活疫苗,7133,2711,4422,61.99%,11.15% B型流感嗜血杆菌,40561,27660,12901,31.81%,32.52% 注射用母牛分枝杆菌(微卡),3389,328,3061,90.31%,7.72% ACYW135群脑膜炎球菌多糖疫苗,14575,539,14036,96.3%,35.38% A群C群脑膜炎球菌多糖结合疫苗,4506,270,4236,94.01%,10.68% 智飞生物,300122,收入构成,报告日期,2008-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 减:内部抵销数,-8946,-8836,-110,1.23%,-0.3% 其他产品,25,17,7,29.93%,0.02% 麻腮风三联,2174,900,1273,58.58%,3.51% 麻风二联,560,196,364,65%,1% A群C脑膜炎球菌多糖疫苗,4919,1271,3648,74.16%,10.05% 甲型肝炎减毒活疫苗,10435,4635,5800,55.58%,15.98% B型流感嗜血杆菌,38867,22536,16331,42.02%,44.99% 注射用母牛分枝杆菌(微卡),2165,198,1967,90.85%,5.42% ACYW135群脑膜炎球菌多糖疫苗,5229,227,5001,95.65%,13.78% A群C群脑膜炎球菌多糖结合疫苗,2172,153,2020,92.98%,5.56% 智飞生物,300122,收入构成,报告日期,2007-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 减:内部抵销数,-4378,-4356,-22,0.5%,-0.08% 其他产品,110,46,64,58.45%,0.23% 麻腮风三联,1694,1106,589,34.74%,2.1% 麻风二联,4934,2113,2821,57.18%,10.06% A群C脑膜炎球菌多糖疫苗,10303,2856,7447,72.28%,26.55% 甲型肝炎减毒活疫苗,13865,6140,7725,55.71%,27.54% B型流感嗜血杆菌,22180,12753,9427,42.5%,33.61%